[Impact of comorbidities for the treatment of heart failure].
Laperche
Thierry
T
Centre cardiologique du Nord, 93200 Saint-Denis. laperche.thierry@orange.fr
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000453:epidemiology; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005602:France / Q000453:epidemiology; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology; D015995:Prevalence; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000453:epidemiology; D051437:Renal Insufficiency / Q000188:drug therapy / Q000453:epidemiology; D012084:Renin-Angiotensin System / Q000187:drug effects; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics
Impact des comorbidités dans la stratégie thérapeutique de l'insuffisance cardiaque.